A Phase 1 interventional study of LY3202328 and Placebo in Dyslipidemias, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-25.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.
Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 37th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 1, and was the 35th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19–80
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 165 across the 47 interventional studies. Of the 42 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 47 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
10 studies in Dyslipidemias by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Dyslipidemias by Eli Lilly and Company, this one is the 8th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 1, and was the 5th registered.
Eli Lilly and Company’s Dyslipidemias studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing atorvastatin in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 10 in Dyslipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single ascending doses of 1 milligram (mg), 3 mg, 10 mg, 30 mg, 100 mg, 300mg, 600 mg LY3202328 orally while fasting, or 30 mg LY3202328 orally while fed in 4 periods.
Drug: LY3202328
A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.
Drug: Placebo
A multiple ascending dose of 5 mg, 20 mg, 100 mg, and 300 mg LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
Drug: LY3202328 · Drug: Atorvastatin · Drug: Simvastatin
A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
Drug: Placebo · Drug: Atorvastatin · Drug: Simvastatin
Administered orally
Administered orally
Administered orally
Administered orally
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B
Number of participants with one or more SAEs in Part A and Part B. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
Time frame: Baseline, Up to 42 Days
Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part A After a Single Dose
Pharmacokinetics (PK) is the maximum plasma concentration (Cmax) of LY3202328 Part A after a single dose.
Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose
PK: Steady State Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part B
PK is the maximum plasma concentration of LY3202328 (Cmax) at steady state in Part B.
Time frame: Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
PK: Area Under the Serum Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY3202328 (LY) in Part A After a Single Dose
PK is the area under the serum concentration time curve from zero to Infinity (AUC\[0-∞\]) of LY3202328 in Part A after a single dose.
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose
PK: Steady State Area Under the Serum Concentration-Time Curve During the Dosing Interval (AUCτ) of LY3202328 (LY) in Part B
PK is the area under the serum concentration-time curve (AUCτ) of LY3202328 at steady state during the dosing interval in Part B.
Time frame: Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
PK: Time to Maximum Concentration (Tmax) of LY3202328 (LY) in Part A
PK is the time to maximum concentration (Tmax) of LY3202328 in Part A
Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96 hours Postdose
PK: Steady State Tmax of LY3202328 (LY) in Part B
PK is the Tmax of LY3202328 at steady state in Part B.
Time frame: Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
Pharmacodynamics (PD): Change From Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A
Pharmacodynamics (PD) is the change from Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A.
Time frame: Predose, 24, 48, 96 Hours Postdose
PD: Change From Baseline to Last Day of Dosing in Fasting HDL-c in Part B
PD is the change from baseline to last day of dosing in fasting HDL-c in Part B.
Time frame: Predose, Days 7, 14, 21, and 28 Postdose
PD: Change From Baseline in Fasting Total Triglycerides Part A
PD is the change from baseline in fasting total triglycerides in Part A.
Time frame: Predose, 24, 48, 96 Hours Postdose
PD: Change From Baseline to Last Day of Dosing in Fasting Total Triglycerides in Part B
PD is the change from baseline to last day of dosing in fasting total triglycerides in Part B.
Time frame: Predose, Days 7, 14, 21, and 28 Postdose
PD: Change From Baseline to in Fasting Total Cholesterol in Part A
PD is the change from baseline in fasting total cholesterol in Part A.
Time frame: Predose, 24, 28, 96 Hours Postdose
PD: Change From Baseline to Last Day of Dosing in Fasting Total Cholesterol in Part B
PD is the change from baseline to last day of dosing in fasting total cholesterol in Part B.
Time frame: Predose, Days 7, 14, 21, and 28 Postdose
PD: Change From Baseline in Fasting Low-Density Lipoprotein Cholesterol (LDL-c) in Part A
PD is the change from baseline in fasting low-density lipoprotein cholesterol (LDL-c) Part A.
Time frame: Predose, 24, 48, 96 Hours Postdose
PD: Change From Baseline to Last Day of Dosing in Fasting LDL-c in Part B
PD is the change from baseline to last day of dosing in fasting LDL-c in Part B.
Time frame: Predose, Days 7, 14, 21, and 28 Postdose
PK: Cmax of Simvastatin With/Without LY3202328 (LY) in Part B
PK: Cmax of Simvastatin with/without LY3202328 (LY) Co-administration in Part B.
Time frame: Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
PK: Area Under Concentration Curve From Zero to Time (AUC [0-t]) of Simvastatin With/Without LY3202328 (LY) in Part B
PK: Area Under Concentration Curve From Zero to Time (AUC \[0-t\]) of Simvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.
Time frame: Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
PK: Cmax of Atorvastatin With/Without LY3202328 (LY) in Part B
PK: Cmax of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B.
Time frame: Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
PK: AUC (0-t) of Atorvastatin With/Without LY3202328 (LY) in Part B
PK: AUC (0-t) of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.
Time frame: Day -7 and Day 28: Predose, 0.5, 1, 2, 4, 4.5, 5, 6, 8, 12, 24 hours Postdose
| Milestone | Part A: Cohort 1(C1), Sequence 1 | Part A: C1, Sequence 2 | Part A: C1, Sequence 3 | Part A: Cohort 2 (C2), Sequence 1 | Part A: C2, Sequence 2 | Part A: C2, Sequence 3 | Part B: C3 (Simvastatin [SS]/Atorvastatin[AS] + 5 mg LY) | Part B: C4 (SS/AS + 20 mg LY) | Part B: C5 (SS/AS + 100 mg LY) | Part B: C6 (SS/AS + 300 mg LY) | Part B: C3-C6 (SS/AS + Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Cohort 1(C1), Sequence 1 | Part A: C1, Sequence 2 | Part A: C1, Sequence 3 | Part A: Cohort 2 (C2), Sequence 1 | Part A: C2, Sequence 2 | Part A: C2, Sequence 3 | Part B: C3 (Simvastatin [SS]/Atorvastatin[AS] + 5 mg LY) | Part B: C4 (SS/AS + 20 mg LY) | Part B: C5 (SS/AS + 100 mg LY) | Part B: C6 (SS/AS + 300 mg LY) | Part B: C3-C6 (SS/AS + Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 3 | 2 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Completed | 3 | 2 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Cohort 1(C1), Sequence 1 | Part A: C1, Sequence 2 | Part A: C1, Sequence 3 | Part A: Cohort 2 (C2), Sequence 1 | Part A: C2, Sequence 2 | Part A: C2, Sequence 3 | Part B: C3 (Simvastatin [SS]/Atorvastatin[AS] + 5 mg LY) | Part B: C4 (SS/AS + 20 mg LY) | Part B: C5 (SS/AS + 100 mg LY) | Part B: C6 (SS/AS + 300 mg LY) | Part B: C3-C6 (SS/AS + Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 2 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 3 | 2 | 2 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Completed | 3 | 2 | 2 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Positive urine drug screen (uds) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Cohort 1(C1), Sequence 1 | Part A: C1, Sequence 2 | Part A: C1, Sequence 3 | Part A: Cohort 2 (C2), Sequence 1 | Part A: C2, Sequence 2 | Part A: C2, Sequence 3 | Part B: C3 (Simvastatin [SS]/Atorvastatin[AS] + 5 mg LY) | Part B: C4 (SS/AS + 20 mg LY) | Part B: C5 (SS/AS + 100 mg LY) | Part B: C6 (SS/AS + 300 mg LY) | Part B: C3-C6 (SS/AS + Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 2 | 3 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 3 | 2 | 3 | 2 | 3 | 2 | 0 | 0 | 0 | 0 | 0 |
| Completed | 3 | 2 | 3 | 2 | 3 | 2 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Positive urinary drug screen (uds) | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Cohort 1(C1), Sequence 1 | Part A: C1, Sequence 2 | Part A: C1, Sequence 3 | Part A: Cohort 2 (C2), Sequence 1 | Part A: C2, Sequence 2 | Part A: C2, Sequence 3 | Part B: C3 (Simvastatin [SS]/Atorvastatin[AS] + 5 mg LY) | Part B: C4 (SS/AS + 20 mg LY) | Part B: C5 (SS/AS + 100 mg LY) | Part B: C6 (SS/AS + 300 mg LY) | Part B: C3-C6 (SS/AS + Placebo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 | 8 | 8 | 8 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 7 | 8 | 6 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Number of participants with one or more SAEs in Part A and Part B. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
| participants | Part A: Placebo | Part A: 1 mg LY3202328 (LY) | Part A: 3 mg LY | Part A: 10 mg LY | Part A: 30 mg LY | Part A: 100 mg LY | Part A: 300 mg LY | Part A: 30 mg LY Fed | Part A: 600 mg LY | Part B: SS/AS/Placebo | Part B: SS/AS/5 mg of LY | Part B: SS/AS/20 mg of LY | Part B: SS/AS/100 mg of LY | Part B: SS/AS/300 mg of LY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Pharmacokinetics (PK) is the maximum plasma concentration (Cmax) of LY3202328 Part A after a single dose.
| nanogram/milliliter (ng/mL) | Part A: 1 mg LY | Part A: 3 mg LY | Part A: 10 mg LY | Part A: 30 mg LY | Part A: 100 mg LY | Part A: 300 mg LY | Part A: 600 mg LY | Part A: 30 mg LY Fed |
|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part A After a Single Dose | 48.258 ± 21.11 | 105.023 ± 26.66 | 340.829 ± 28.99 | 581.782 ± 32.29 | 1600.953 ± 40.01 | 1632.595 ± 42.84 | 2866.855 ± 51.29 | 1105.999 ± 18.47 |
PK is the maximum plasma concentration of LY3202328 (Cmax) at steady state in Part B.
| ng/ml | Part B: 5 mg LY | Part B: 20 mg LY | Part B: 100 mg LY | Part B: 300 mg LY |
|---|---|---|---|---|
| PK: Steady State Maximum Plasma Concentration (Cmax) of LY3202328 (LY) in Part B | 445.858 ± 32.78 | 882.125 ± 32.81 | 3687.167 ± 34.83 | 3209.396 ± 37.31 |
PK is the area under the serum concentration time curve from zero to Infinity (AUC\[0-∞\]) of LY3202328 in Part A after a single dose.
| ng/mL | Part A: 1 mg LY | Part A: 3 mg of LY | Part A: 10 mg LY | Part A: 30 mg LY | Part A: 100 mg of LY | Part A: 300 mg LY | Part A: 600 mg LY | Part A: 30 mg LY Fed |
|---|---|---|---|---|---|---|---|---|
| PK: Area Under the Serum Concentration Time Curve From Zero to Infinity (AUC[0-∞]) of LY3202328 (LY) in Part A After a Single Dose | NA ± NA | NA ± NA | 7726.17 ± 45.23 | 17018.43 ± 62.60 | 55406.24 ± 41.35 | 66185.70 ± 71.44 | NA ± NA | 28415.22 ± 56.67 |
PK is the area under the serum concentration-time curve (AUCτ) of LY3202328 at steady state during the dosing interval in Part B.
| hour*nanogram/milliliter(hr*ng/ml) | Part B: 5 mg LY | Part B: 20 mg LY | Part B: 100 mg LY | Part B: 300 mg LY |
|---|---|---|---|---|
| PK: Steady State Area Under the Serum Concentration-Time Curve During the Dosing Interval (AUCτ) of LY3202328 (LY) in Part B | 7587.24 ± 38.612 | 13362.44 ± 44.984 | 67499.80 ± 37.465 | 50774.85 ± 43.861 |
PK is the time to maximum concentration (Tmax) of LY3202328 in Part A
| hour (hr) | Part A: 1 mg LY | Part A: 3 mg LY | Part A: 10 mg LY | Part A: 30 mg LY | Part A: 100 mg LY | Part A: 300 mg LY | Part A: 600 mg LY | Part A: 30 mg LY Fed |
|---|---|---|---|---|---|---|---|---|
| PK: Time to Maximum Concentration (Tmax) of LY3202328 (LY) in Part A | 2.02 (1.0 to 4.0) | 3.52 (2.0 to 6.2) | 4.0 (2.0 to 6.0) | 4.00 (3.0 to 4.1) | 6.00 (2.0 to 8.0) | 4.02 (3.0 to 8.0) | 4.00 (2.0 to 24.0) | 5.00 (4.0 to 8.0) |
PK is the Tmax of LY3202328 at steady state in Part B.
| hr | Part B: 5 mg LY | Part B: 20 mg LY | Part B: 100 mg LY | Part B: 300 mg LY |
|---|---|---|---|---|
| PK: Steady State Tmax of LY3202328 (LY) in Part B | 2.00 (2.0 to 6.0) | 4.20 (4.0 to 6.0) | 3.00 (2.0 to 4.0) | 3.04 (1.0 to 6.0) |
Pharmacodynamics (PD) is the change from Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c) in Part A.
| millimole/Liter (mmol/L) | Part A: Placebo | Part A: 1 mg LY | Part A: 3 mg LY | Part A: 10 mg LY | Part A: 30 mg LY | Part A: 100 mg LY | Part A: 300 mg LY | Part A: 600 mg LY |
|---|---|---|---|---|---|---|---|---|
| 24 Hours | -0.003 ± 0.1155 | -0.030 ± 0.0842 | -0.043 ± 0.0454 | -0.047 ± 0.0740 | -0.026 ± 0.0433 | 0.052 ± 0.1099 | -0.004 ± 0.0684 | 0.010 ± 0.0232 |
| 48 Hours | -0.037 ± 0.1560 | -0.039 ± 0.0217 | 0.009 ± 0.1387 | -0.043 ± 0.0950 | -0.026 ± 0.1010 | 0.019 ± 0.0978 | -0.009 ± 0.1551 | -0.052 ± 0.0755 |
| 96 Hours | -0.074 ± 0.1258 | -0.073 ± 0.1241 | -0.086 ± 0.0892 | -0.134 ± 0.0553 | -0.030 ± 0.1304 | -0.091 ± 0.1206 | -0.082 ± 0.1487 | -0.005 ± 0.1411 |
PD is the change from baseline to last day of dosing in fasting HDL-c in Part B.
| mmol/L | Part B: Placebo | Part B: 5 mg LY | Part B: 20 mg LY | Part B: 100 mg LY | Part B: 300 mg LY |
|---|---|---|---|---|---|
| PD: Change From Baseline to Last Day of Dosing in Fasting HDL-c in Part B | 0.008 ± 0.1169 | -0.010 ± 0.1165 | -0.101 ± 0.0812 | -0.107 ± 0.1894 | -0.101 ± 0.0621 |
PD is the change from baseline in fasting total triglycerides in Part A.
| mmol/L | Part A: Placebo | Part A: 1 mg LY | Part A: 3 mg LY | Part A: 10 mg LY | Part A: 30 mg LY | Part A: 100 mg LY | Part A: 300 mg LY | Part A: 600 mg LY |
|---|---|---|---|---|---|---|---|---|
| 24 Hours | -0.276 ± 0.2043 | -0.397 ± 0.2877 | -0.190 ± 0.1491 | -0.386 ± 0.2766 | -0.311 ± 0.2831 | -0.523 ± 0.5801 | -0.064 ± 0.1455 | -0.302 ± 0.2318 |
| 48 Hours | -0.320 ± 0.3162 | -0.269 ± 0.2260 | -0.115 ± 0.2643 | -0.260 ± 0.3382 | -0.418 ± 0.3290 | -0.766 ± 0.5870 | -0.226 ± 0.3646 | -0.198 ± 0.1345 |
| 96 Hours | -0.239 ± 0.3227 | -0.209 ± 0.6817 | -0.132 ± 0.2349 | 0.013 ± 0.7179 | -0.331 ± 0.4343 | -0.455 ± 0.5144 | -0.326 ± 0.3549 | 0.158 ± 0.6773 |
PD is the change from baseline to last day of dosing in fasting total triglycerides in Part B.
| mmol/L | Part B: Placebo | Part B: 5 mg LY | Part B: 20 mg LY | Part B: 100 mg LY | Part B: 300 mg LY |
|---|---|---|---|---|---|
| PD: Change From Baseline to Last Day of Dosing in Fasting Total Triglycerides in Part B | 0.205 ± 0.6757 | -0.131 ± 0.2720 | -0.231 ± 0.5383 | 0.020 ± 0.6281 | -0.480 ± 0.5235 |
PD is the change from baseline in fasting total cholesterol in Part A.
| mmol/L | Part A: Placebo | Part A: 1 mg LY | Part A: 3 mg LY | Part A: 10 mg LY | Part A: 30 mg LY | Part A: 100 mg LY | Part A: 300 mg LY | Part A: 600 mg LY |
|---|---|---|---|---|---|---|---|---|
| 24 Hours | 0.085 ± 0.3075 | -0.186 ± 0.2699 | -0.013 ± 0.2850 | -0.203 ± 0.2157 | 0.073 ± 0.1863 | 0.285 ± 0.1903 | 0.203 ± 0.2421 | 0.093 ± 0.1560 |
| 48 Hours | -0.085 ± 0.4618 | -0.436 ± 0.2608 | -0.030 ± 0.2218 | -0.376 ± 0.2321 | -0.013 ± 0.3981 | 0.091 ± 0.3654 | 0.134 ± 0.5446 | -0.026 ± 0.4719 |
| 96 Hours | -0.318 ± 0.4288 | -0.527 ± 0.3262 | -0.207 ± 0.2949 | -0.609 ± 0.2635 | -0.199 ± 0.4732 | -0.317 ± 0.6296 | -0.155 ± 0.4826 | -0.041 ± 0.6020 |
PD is the change from baseline to last day of dosing in fasting total cholesterol in Part B.
| mmol/L | Part B: Placebo | Part B: 5 mg LY | Part B: 20 mg LY | Part B: 100 mg LY | Part B: 300 mg LY |
|---|---|---|---|---|---|
| PD: Change From Baseline to Last Day of Dosing in Fasting Total Cholesterol in Part B | 0.206 ± 0.3615 | 0.118 ± 0.3840 | 0.183 ± 0.4681 | 0.174 ± 0.4963 | -0.190 ± 0.4425 |
PD is the change from baseline in fasting low-density lipoprotein cholesterol (LDL-c) Part A.
| mmol/L | Part A: Placebo | Part A: 1 mg LY | Part A: 3 mg LY | Part A: 10 mg LY | Part A: 30 mg LY | Part A: 100 mg LY | Part A: 300 mg LY | Part A: 600 mg LY |
|---|---|---|---|---|---|---|---|---|
| 24 Hours | 0.231 ± 0.2513 | 0.025 ± 0.2205 | 0.117 ± 0.2400 | 0.020 ± 0.2328 | 0.241 ± 0.1594 | 0.471 ± 0.3418 | 0.236 ± 0.2429 | 0.163 ± 0.1608 |
| 48 Hours | 0.111 ± 0.4026 | -0.275 ± 0.3004 | 0.013 ± 0.2093 | -0.214 ± 0.2378 | 0.203 ± 0.3400 | 0.419 ± 0.3293 | 0.245 ± 0.3457 | -0.001 ± 0.3891 |
| 96 Hours | -0.109 ± 0.4147 | -0.358 ± 0.4170 | -0.061 ± 0.1747 | -0.481 ± 0.3681 | -0.018 ± 0.3048 | -0.020 ± 0.6327 | 0.075 ± 0.2565 | 0.038 ± 0.6305 |
PD is the change from baseline to last day of dosing in fasting LDL-c in Part B.
| mmol/L | Part B: Placebo | Part B: 5 mg LY | Part B: 20 mg LY | Part B: 100 mg LY | Part B: 300 mg LY |
|---|---|---|---|---|---|
| PD: Change From Baseline to Last Day of Dosing in Fasting LDL-c in Part B | 0.103 ± 0.4114 | 0.184 ± 0.3419 | 0.388 ± 0.4876 | 0.227 ± 0.4494 | 0.131 ± 0.4225 |
PK: Cmax of Simvastatin with/without LY3202328 (LY) Co-administration in Part B.
| ng/ml | Simvastatin With LY (Test) | Simvastatin Alone (Reference) |
|---|---|---|
| Placebo | 2.906 ± 18.72 | 2.061 ± 71.24 |
| 5 mg LY | 2.388 ± 58.17 | 3.374 ± 52.99 |
| 20 mg LY | 3.576 ± 19.35 | 3.274 ± 26.87 |
| 100 mg LY | 4.634 ± 55.59 | 4.303 ± 25.45 |
| 300 mg LY | 4.221 ± 58.78 | 1.979 ± 55.84 |
PK: Area Under Concentration Curve From Zero to Time (AUC \[0-t\]) of Simvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.
| hr*ng/ml | Simvastatin With LY (Test) | Simvastatin Alone (Reference) |
|---|---|---|
| Placebo | 9.648 ± 38.82 | 6.250 ± 61.54 |
| 5 mg LY | 6.668 ± 42.96 | 9.287 ± 57.54 |
| 20 mg LY | 9.697 ± 26.81 | 7.960 ± 32.21 |
| 100 mg LY | 14.269 ± 53.78 | 10.434 ± 26.20 |
| 300 mg LY | 11.908 ± 60.19 | 8.951 ± 61.65 |
PK: Cmax of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B.
| ng/mL | Atorvastatin With LY (Test) | Atorvastatin Alone (Reference) |
|---|---|---|
| Placebo | 3.479 ± 20.58 | 3.575 ± 30.44 |
| 5 mg LY | 2.840 ± 27.96 | 3.621 ± 82.05 |
| 20 mg LY | 1.238 ± 38.05 | 1.286 ± 45.27 |
| 100 mg LY | 2.511 ± 32.17 | 3.105 ± 51.95 |
| 300 mg LY | 1.489 ± 42.11 | 1.376 ± 59.68 |
PK: AUC (0-t) of Atorvastatin with/without LY3202328 (LY) Co-administration in Part B. AUC from time 0 to time t, where t is the time of last quantifiable plasma concentration.
| hr*ng/ml | Atorvastatin With LY (Test) | Atorvastatin Alone (Reference) |
|---|---|---|
| Placebo | 15.874 ± 32.81 | 16.518 ± 33.88 |
| 5 mg LY | 17.311 ± 6.35 | 14.913 ± 48.97 |
| 20 mg LY | 7.921 ± 57.94 | 7.952 ± 63.04 |
| 100 mg LY | 11.983 ± 38.63 | 13.207 ± 61.25 |
| 300 mg LY | 7.748 ± 50.04 | 9.111 ± 36.39 |
Collected over From Baseline to End of Study (Up to 10 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/25 (0%) | 0/25 (0%) | 2/25 (8%) |
| 1 mg LY3202328 (LY) | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| 3 mg LY | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| 5 mg LY | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| 10 mg LY | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| 20 mg LY | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| 30 mg LY | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 30 mg LY Fed | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| 100 mg LY | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| 300 mg LY | 0/14 (0%) | 2/14 (14.3%) | 6/14 (42.9%) |
| 600 mg of LY | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Event | Placebo | 1 mg LY3202328 (LY) | 3 mg LY | 5 mg LY | 10 mg LY | 20 mg LY | 30 mg LY | 30 mg LY Fed | 100 mg LY | 300 mg LY | 600 mg of LY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/25 | 0/6 | 0/6 | 0/8 | 0/6 | 0/8 | 0/6 | 0/4 | 0/12 | 1/14 | 0/5 |
| Aspartate aminotransferase increasedInvestigations | 0/25 | 0/6 | 0/6 | 0/8 | 0/6 | 0/8 | 0/6 | 0/4 | 0/12 | 1/14 | 0/5 |
| Event | Placebo | 1 mg LY3202328 (LY) | 3 mg LY | 5 mg LY | 10 mg LY | 20 mg LY | 30 mg LY | 30 mg LY Fed | 100 mg LY | 300 mg LY | 600 mg of LY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/25 | 0/6 | 0/6 | 2/8 | 1/6 | 2/8 | 0/6 | 0/4 | 1/12 | 2/14 | 0/5 |
| Pr interval prolongedInvestigations | 0/25 | 0/6 | 0/6 | 0/8 | 1/6 | 0/8 | 0/6 | 0/4 | 0/12 | 0/14 | 0/5 |
| PapuleSkin and subcutaneous tissue disorders | 0/25 | 0/6 | 0/6 | 0/8 | 0/6 | 0/8 | 1/6 | 0/4 | 0/12 | 0/14 | 0/5 |
| DiarrheaGastrointestinal disorders | 0/25 | 0/6 | 0/6 | 0/8 | 0/6 | 1/8 | 0/6 | 0/4 | 0/12 | 0/14 | 0/5 |
| FlatulenceGastrointestinal disorders | 0/25 | 0/6 | 0/6 | 1/8 | 0/6 | 0/8 | 0/6 | 0/4 | 0/12 | 0/14 | 0/5 |
| NauseaGastrointestinal disorders | 0/25 | 0/6 | 0/6 | 0/8 | 0/6 | 1/8 | 0/6 | 0/4 | 0/12 | 1/14 | 0/5 |
| FatigueGeneral disorders | 0/25 | 0/6 | 0/6 | 1/8 | 0/6 | 0/8 | 0/6 | 0/4 | 0/12 | 0/14 | 0/5 |
| Kidney infectionInfections and infestations | 0/25 | 0/6 | 0/6 | 0/8 | 0/6 | 1/8 | 0/6 | 0/4 | 0/12 | 0/14 | 0/5 |
| Pain in hipMusculoskeletal and connective tissue disorders | 0/25 | 0/6 | 0/6 | 0/8 | 0/6 | 1/8 | 0/6 | 0/4 | 0/12 | 0/14 | 0/5 |
| Stiff neckMusculoskeletal and connective tissue disorders | 0/25 | 0/6 | 0/6 | 1/8 | 0/6 | 1/8 | 0/6 | 0/4 | 0/12 | 0/14 | 0/5 |
All participants who received at least one dose of study drug in Part A and Part B.
| Age, Continuous(years) | Part A, C1, Sequence 1 | Part A, C1, Sequence 2 | Part A, C1, Sequence 3 | Part A, C2, Sequence 1 | Part A, C2, Sequence 2 | Part A, C2, Sequence 3 | Part B: SS/AS/Placebo | Part B: SS/AS/5 mg LY | Part B: SS/AS/20 mg LY | Part B: SS/AS/100 mg LY | Part B: SS/AS/300 mg LY | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 48.3 ± 8.02 | 56.0 ± 12.12 | 58.5 ± 4.04 | 34.0 ± 13.53 | 38.3 ± 22.50 | 54.7 ± 17.21 | 54.0 ± 9.12 | 50.5 ± 12.76 | 46.8 ± 13.13 | 55.0 ± 10.18 | 36.9 ± 10.80 | 48.7 ± 13.22 |
| Sex: Female, Male(Participants) | Part A, C1, Sequence 1 | Part A, C1, Sequence 2 | Part A, C1, Sequence 3 | Part A, C2, Sequence 1 | Part A, C2, Sequence 2 | Part A, C2, Sequence 3 | Part B: SS/AS/Placebo | Part B: SS/AS/5 mg LY | Part B: SS/AS/20 mg LY | Part B: SS/AS/100 mg LY | Part B: SS/AS/300 mg LY | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 2 | 0 | 0 | 1 | 4 | 4 | 3 | 4 | 1 | 21 |
| Male | 3 | 2 | 2 | 3 | 3 | 2 | 4 | 4 | 5 | 4 | 7 | 39 |
| Ethnicity (NIH/OMB)(Participants) | Part A, C1, Sequence 1 | Part A, C1, Sequence 2 | Part A, C1, Sequence 3 | Part A, C2, Sequence 1 | Part A, C2, Sequence 2 | Part A, C2, Sequence 3 | Part B: SS/AS/Placebo | Part B: SS/AS/5 mg LY | Part B: SS/AS/20 mg LY | Part B: SS/AS/100 mg LY | Part B: SS/AS/300 mg LY | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 0 | 5 | 0 | 0 | 7 | 2 | 15 |
| Not Hispanic or Latino | 4 | 3 | 4 | 2 | 3 | 3 | 3 | 8 | 8 | 1 | 6 | 45 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A, C1, Sequence 1 | Part A, C1, Sequence 2 | Part A, C1, Sequence 3 | Part A, C2, Sequence 1 | Part A, C2, Sequence 2 | Part A, C2, Sequence 3 | Part B: SS/AS/Placebo | Part B: SS/AS/5 mg LY | Part B: SS/AS/20 mg LY | Part B: SS/AS/100 mg LY | Part B: SS/AS/300 mg LY | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 1 | 3 | 2 | 1 | 1 | 2 | 0 | 0 | 0 | 13 |
| White | 2 | 2 | 3 | 0 | 1 | 2 | 7 | 6 | 8 | 8 | 8 | 47 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A, C1, Sequence 1 | Part A, C1, Sequence 2 | Part A, C1, Sequence 3 | Part A, C2, Sequence 1 | Part A, C2, Sequence 2 | Part A, C2, Sequence 3 | Part B: SS/AS/Placebo | Part B: SS/AS/5 mg LY | Part B: SS/AS/20 mg LY | Part B: SS/AS/100 mg LY | Part B: SS/AS/300 mg LY | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 4 | 3 | 4 | 3 | 3 | 3 | 8 | 8 | 8 | 8 | 8 | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Mar 2016, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.
Results were first posted in May 2021, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atorvastatin · Simvastatin